Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry
出版年份 2017 全文链接
标题
Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry
作者
关键词
-
出版物
ARTHRITIS CARE & RESEARCH
Volume 69, Issue 4, Pages 552-560
出版商
Wiley
发表日期
2016-07-07
DOI
10.1002/acr.22961
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Incidence of herpes zoster infections in juvenile idiopathic arthritis patients
- (2015) S. Nimmrich et al. RHEUMATOLOGY INTERNATIONAL
- Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
- (2015) Rebecca Davies et al. Arthritis & Rheumatology
- A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors
- (2014) Heather M. Walters et al. CLINICAL RHEUMATOLOGY
- Extension Study of Participants from the Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis
- (2014) C. A. Wallace et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry
- (2014) Heinrike Schmeling et al. Arthritis & Rheumatology
- Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
- (2013) Zbigniew Zuber et al. MEDICAL SCIENCE MONITOR
- Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment
- (2012) Timothy Beukelman et al. ARTHRITIS AND RHEUMATISM
- Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
- (2011) A. Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis
- (2011) Carol A. Wallace et al. ARTHRITIS AND RHEUMATISM
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features
- (2011) Timothy Beukelman et al. ARTHRITIS CARE & RESEARCH
- Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis
- (2009) E. H. Giannini et al. ARTHRITIS AND RHEUMATISM
- Development and validation of a composite disease activity score for juvenile idiopathic arthritis
- (2009) Alessandro Consolaro et al. ARTHRITIS AND RHEUMATISM
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
- (2009) Anja Strangfeld JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
- (2009) Daniel E. Furst SEMINARS IN ARTHRITIS AND RHEUMATISM
- Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
- (2008) F H M Prince et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry
- (2008) G Horneff et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
- (2008) Daniel J. Lovell et al. ARTHRITIS AND RHEUMATISM
- Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
- (2008) Daniel J. Lovell et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started